Hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer represents the most prevalent clinical subtype globally, accounting for nearly seventy percent of all diagnosed cases. However, clinicians continue to encounter substantial challenges because this malignancy lacks simple, noninvasive biomarkers to monitor long-term recurrence risks effectively. Recently, a pivotal study evaluated preoperative circulating eosinophil count as an innovative, clinically applicable liquid biopsy biomarker for this patient population. By analyzing routine peripheral blood counts alongside comprehensive multiomic tumor profiling, investigators uncovered profound connections between peripheral granulocytes and host antitumor immunity. Furthermore, their findings establish that peripheral eosinophils provide critical additive prognostic information and predict therapeutic response to targeted interventions. Consequently, this readily accessible hematologic metric may soon transform everyday risk stratification and adjuvant decision-making in clinical oncology.

Circulating Eosinophil Count as a Prognostic Liquid Biopsy

Historically, clinicians have regarded eosinophils primarily as frontline responders in allergic reactions and parasitic infections. Nevertheless, accumulating translational evidence indicates that these granulocytes play decisive roles in shaping solid tumor microenvironments. In this rigorous multicenter study, researchers investigated preoperative peripheral blood differentials across a multimodal discovery cohort comprising 472 patients with HR+/HER2- breast cancer. Furthermore, the investigative team validated their primary clinical observations across an independent expanded cohort of 23,170 patients using propensity score overlap weighting. Importantly, higher baseline circulating eosinophil numbers strongly correlated with significantly superior recurrence-free survival and distant metastasis-free survival. These associations remained robust even after adjusting for conventional clinicopathological risk factors, including tumor size, histologic grade, and axillary lymph node involvement. In addition, patients exhibiting elevated peripheral counts experienced a markedly reduced risk of late distant metastases. Therefore, the peripheral blood differential count provides immediate, accessible prognostic intelligence without requiring costly genomic testing or invasive tissue extraction. Consequently, oncologists can integrate this standard hematologic parameter into routine initial staging evaluations to refine risk prediction and tailor surveillance schedules for patients facing early-stage disease.

Mechanistic Links Between Eosinophils and Antitumor Immunity

To elucidate the precise biological mechanisms driving these improved outcomes, investigators conducted comprehensive multiomic profiling and high-resolution spatial digital pathology. Specifically, genomic analyses revealed that patients with higher circulating eosinophil counts displayed lower human leukocyte antigen (HLA) homozygosity. This pronounced immunogenetic diversity significantly enhances tumor neoantigen presentation, thereby fostering sustained systemic immune activation. Moreover, spatial digital pathology demonstrated that tumor-infiltrating eosinophils consistently coaggregated with cytotoxic CD8 T lymphocytes within the tumor stroma. Rather than exerting tumoricidal activity in complete isolation, eosinophils appear to guide and activate cytotoxic lymphocytes through chemokine signaling networks. To confirm this functional hypothesis in vivo, researchers performed adoptive transfer experiments using both EMT6 and E0771 immunocompetent murine breast cancer models. Notably, adoptive transfer of functional eosinophils markedly suppressed primary tumor growth and curtailed metastatic colonization. In contrast, targeted depletion of circulating eosinophils accelerated tumor expansion and reduced intratumoral CD8 T-cell density. Therefore, peripheral eosinophil counts do not merely reflect nonspecific background inflammation. Instead, they serve as a faithful surrogate for active, host-mediated antitumor immunity that directly impedes malignant dissemination.

Synergy With the 21-Gene Recurrence Score

Currently, medical oncologists rely heavily on multigene expression assays, such as the 21-gene recurrence score, to guide adjuvant systemic chemotherapy decisions. However, these tissue-based genomic panels evaluate only intrinsic tumor cell biology while completely overlooking systemic host immune competence. To address this critical prognostic limitation, the investigators assessed whether baseline eosinophil levels could provide additive value in 2,973 patients with available 21-gene recurrence scores. Remarkably, incorporating circulating eosinophil metrics alongside the 21-gene recurrence score dramatically refined recurrence risk stratification across all risk categories. For instance, among patients categorized with intermediate or high recurrence scores, those harboring higher eosinophil counts experienced significantly fewer distant relapses than individuals with low counts. Conversely, low baseline eosinophil numbers uncovered a vulnerable patient subset with elevated residual recurrence risk despite favorable genomic profiles. Thus, systemic immune status profoundly modifies the actual disease trajectory predicted by tumor-intrinsic genomic signatures alone. Furthermore, integrating this peripheral biomarker empowers clinicians to achieve personalized risk modeling without imposing any added financial burden. As a result, multidisciplinary care teams can make far more informed adjuvant chemotherapy recommendations.

Predicting Therapeutic Benefit From CDK4/6 Inhibitors

Adjuvant treatment combining cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with endocrine therapy represents the established standard of care for high-risk HR+/HER2- early breast cancer. Nevertheless, individual therapeutic responses vary substantially, and these targeted agents carry risks of serious hematologic toxicities and substantial financial toxicity. In this landmark study, researchers evaluated 3,471 high-risk patients to investigate whether systemic immune profiles govern targeted therapy efficacy. Interestingly, circulating eosinophil counts successfully predicted the precise magnitude of clinical benefit derived from adjuvant CDK4/6 inhibition. High-risk patients presenting with elevated baseline eosinophil counts achieved pronounced disease-free survival advantages from CDK4/6 inhibitor therapy. In contrast, patients with suppressed peripheral eosinophils experienced minimal incremental benefit from adding CDK4/6 inhibitors to endocrine backbones. Biologically, CDK4/6 inhibitors augment tumor immunogenicity by inducing antigen presentation and attenuating immunosuppressive regulatory T cells. Because eosinophils prime the local microenvironment for effective lymphocyte infiltration, an immune-competent baseline status enables CDK4/6 inhibitors to exert maximal antitumor activity. Consequently, assessing peripheral blood eosinophils prior to therapy initiation could assist oncologists in selecting patients most likely to derive genuine therapeutic gain.

Clinical Implementation in Indian Oncology Practice

The translational implications of these findings are particularly profound for clinical oncology practice across India and similar resource-constrained environments. Breast cancer remains the most frequently diagnosed malignancy among Indian women, often presenting at relatively younger ages and with advanced stages. Furthermore, expensive multigene prognostic assays remain inaccessible for the vast majority of Indian patients due to high out-of-pocket medical expenditures. In sharp contrast, a routine complete blood count with differential is universally available, standardized, and remarkably economical across primary, secondary, and tertiary healthcare centers throughout India. Therefore, adopting circulating eosinophil counts as a routine prognostic biomarker can immediately democratize risk stratification across diverse socioeconomic populations. Indian oncologists can seamlessly integrate this metric into multidisciplinary tumor boards to refine long-term surveillance intensity and guide shared treatment decisions. Additionally, identifying patients with robust systemic immune activation may help prevent overtreatment while optimizing resource allocation for expensive targeted regimens. Ultimately, linking peripheral blood counts with tumor immunobiology transforms a ubiquitous laboratory test into a powerful prognostic asset for clinical breast oncology.

Frequently Asked Questions

How does circulating eosinophil count influence breast cancer prognosis?

A higher circulating eosinophil count indicates robust systemic immune activation and enhanced tumor surveillance in hormone receptor-positive breast cancer. Functionally, peripheral eosinophils migrate into malignant stroma, where they release chemoattractants that recruit cytotoxic CD8 T cells. Furthermore, elevated counts correlate with greater HLA genetic diversity, which improves neoantigen presentation. Consequently, patients with higher baseline eosinophils exhibit significantly reduced recurrence rates and superior distant metastasis-free survival compared to those with lower counts.

Can eosinophil measurements replace multigene recurrence panels like Oncotype DX?

Peripheral eosinophil counts cannot completely replace established multigene recurrence assays like the 21-gene score. However, circulating eosinophils offer powerful additive prognostic value by evaluating systemic host immunity, which genomic assays completely overlook. By combining peripheral blood differentials with molecular recurrence scores, oncologists can identify high-risk individuals more accurately. Additionally, this cost-effective parameter provides vital clinical guidance for patients who cannot afford expensive multigene genomic testing in resource-limited healthcare environments.

How do baseline eosinophil levels predict responsiveness to CDK4/6 inhibitors?

Recent clinical evidence demonstrates that high-risk breast cancer patients with higher baseline eosinophils derive significantly greater therapeutic benefit from adjuvant CDK4/6 inhibitors. CDK4/6 inhibitors enhance tumor immunogenicity by augmenting antigen presentation and suppressing regulatory T cells. Because eosinophils actively recruit effector T lymphocytes into tumors, an immune-competent baseline environment allows CDK4/6 inhibitors to trigger more effective antitumor responses. Conversely, patients with low eosinophil counts exhibit diminished long-term clinical responses to these targeted agents.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should rely on their clinical judgment and verify details independently. Refer to the latest local and national guidelines for clinical practice.

References

1. Li ZQ et al. Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2026 Oct 20. doi: 10.1200/JCO-26-00261. PMID: 42900864.
2. Grisaru-Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer. 2020;20(10):594-607. doi: 10.1038/s41568-020-0283-9.
3. Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi: 10.1038/s41572-019-0111-2.